Response to paclitaxel in adenoid cystic carcinoma of the salivary glands

@article{Till2008ResponseTP,
  title={Response to paclitaxel in adenoid cystic carcinoma of the salivary glands},
  author={Brian G. Till and Renato G Martins},
  journal={Head \& Neck},
  year={2008},
  volume={30}
}
Paclitaxel is not considered to be an active drug in adenoid cystic carcinoma (ACC) of the salivary glands. We report 2 consecutive cases of patients with ACC who responded to paclitaxel. 
View on Wiley
sbccp.org.br
9 Citations
Background Citations
6
Results Citations
1

9 Citations

Citation Type

Citation Type

Metastatic adenoid cystic carcinoma of the salivary gland responding to cetuximab plus weekly paclitaxel after no response to weekly paclitaxel alone
TLDR
In cases in which chemotherapy is indicated, resistance is a common phenomenon and new drugs, such as cetuximab, have been chosen to avoid this chemoresistance.
Clinically Integrated Molecular Diagnostics in Adenoid Cystic Carcinoma
TLDR
The need for more effective, biomarker‐informed therapies in rare cancers is addressed, focusing on clinical utility and financial sustainability of integrated next‐generation sequencing in routine practice.
Weekly paclitaxel plus cetuximab reduces the lung metastasis of adenoid cystic carcinoma arising from the salivary gland
Salivary Gland Malignancies.
Cyclophosphamide, doxorubicin, and cisplatin in advanced salivary gland cancer.
TLDR
A retrospective study confirms the clinically meaningful efficacy of CAP in advanced adenocarcinomas NOS of the salivary gland in routine practice, with acceptable safety levels.
Adenoid Cystic Carcinoma
TLDR
Adenoid cystic carcinoma has a slow but relentless progression with long-term (15–20 years) fatal outcome inasmuch as 60–90 % of cases and is hence always best regarded as a high-grade malignancy.
Salivary Gland Tumors
TLDR
The high percentage of vascular tumors reported by many authors exceeds the number of cases registered with the Armed Force Institute of Pathology (AFIP); however, the large experience of the AFIP reports benign ­mesenchymal tumors occurring in only 12.3% of cases.
Breast carcinoma--rare types: review of the literature.
TLDR
This review brings updated information on 16 epithelial subtypes as classified by the WHO system with a very concise histopathology description and parameters helpful in the clinic to enable a better understanding of the disease and its optimal approach to therapy.
Rare types of breast carcinoma
TLDR
The aim of this retrospective study was to analyze the data on rare breast cancers, to describe their main characteristics, and to calculate survival rates.

References

SHOWING 1-9 OF 9 REFERENCES
Phase II trial of taxol in salivary gland malignancies (E1394): A trial of the Eastern Cooperative Oncology Group
TLDR
The Eastern Cooperative Oncology Group (ECOG) initiated a phase II evaluation of paclitaxel in patients with locally recurrent or metastatic salivary gland malignancies.
Systemic therapy in the palliative management of advanced salivary gland cancers.
  • S. Laurie, L. Licitra
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2006
TLDR
There is a need for a determined, coordinated effort to conduct high-quality clinical trials in patients with advanced salivary gland cancer of these histologies, with an emphasis on the potential role of targeted agents.
Adenoid cystic carcinoma of the head and neck: a review
  • P. Bradley
  • Medicine
    Current opinion in otolaryngology & head and neck surgery
  • 2004
TLDR
The time is now opportune for a multicenter, randomized, controlled trial to identify patients who would benefit from adjuvant radiotherapy and/or chemotherapy in the control of locoregional recurrences and the prevention of distant metastases.
Salivary gland carcinoma treated with concomitant chemoradiation with intraarterial cisplatin and docetaxel
TLDR
The concomitant chemoradiotherapy of cisplatin and docetaxel seemed to be a practicable option for patients with recurrent and unresectable salivary gland carcinomas.
Factors influencing survival rate in adenoid cystic carcinoma of the salivary glands.
TLDR
It is concluded that tumour site, clinical stage and histological type are the important factors influencing the prognosis of patients with adenoid cystic carcinoma.
Paclitaxel and carboplatin for recurrent salivary gland malignancies.
TLDR
This combination had a moderate activity; the treatment was well tolerated and toxicity was manageable; the median survival time was 13.5 months for PR/NC patients, 6 months for non responders; median overall survival was 12.5 years.
Chemoradiotherapy for Adenoid Cystic Carcinoma: Preliminary Results of an Organ Sparing Approach
TLDR
Preliminary data suggest that carboplatinum/paclitaxel based CRT for ACC provides local regional control and is a potential alternative to surgery or radiotherapy for patients with locally advanced ACC.
Protein expression profiling identifies maspin and stathmin as potential biomarkers of adenoid cystic carcinoma of the salivary glands
Adenoid Cystic Carcinoma of the Major Salivary Glands Treated With Surgery and Radiation